The determination and interpretation of the therapeutic index in drug development

A key part of drug discovery and development is the characterization and optimization of the safety and efficacy of drug candidates to identify those that have an appropriately balanced safety–efficacy profile for a given indication. The therapeutic index (TI) — which is typically considered as the ratio of the highest exposure to the drug that results in no toxicity to the exposure that produces the desired efficacy — is an important parameter in efforts to achieve this balance. Various types of safety and efficacy data are generated in vitro and in vivo (in animals and in humans), and these data can be used to predict the clinical TI of a drug candidate at an early stage. However, approaches to systematically and quantitatively compare these types of data and to apply this knowledge more effectively are needed. This article critically discusses the various aspects of TI determination and interpretation in drug development for both small molecule drugs and biotherapeutics.

[1]  Takashi Usui,et al.  Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance–associated protein 2 , 2007, Biopharmaceutics & drug disposition.

[2]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[3]  Ian D. Wilson,et al.  Managing the challenge of chemically reactive metabolites in drug development , 2011, Nature Reviews Drug Discovery.

[4]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[5]  Patrick Y Muller,et al.  Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing. , 2011, Advanced drug delivery reviews.

[6]  Peter Lloyd,et al.  The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. , 2009, Current opinion in biotechnology.

[7]  Richard W. Lewis,et al.  Recognition of Adverse and Nonadverse Effects in Toxicity Studies , 2002, Toxicologic pathology.

[8]  John C. Dearden,et al.  In silico prediction of drug toxicity , 2003, J. Comput. Aided Mol. Des..

[9]  Oprs Alert.  Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .

[10]  J. Valentin,et al.  On the relationship between block of the cardiac Na+ channel and drug‐induced prolongation of the QRS complex , 2011, British journal of pharmacology.

[11]  J. Verweij,et al.  The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.

[12]  D A Smith,et al.  The use of C(av) rather than AUC in safety assessment. , 2010, Regulatory toxicology and pharmacology : RTP.

[13]  Frank Dieterle,et al.  Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring , 2009, Expert opinion on drug metabolism & toxicology.

[14]  Aaron S Kesselheim,et al.  The role of litigation in defining drug risks. , 2007, JAMA.

[15]  J. Wu-Wong,et al.  Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics. , 1997, The Journal of pharmacology and experimental therapeutics.

[16]  P. Oh,et al.  Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. , 1994, The Journal of biological chemistry.

[17]  Daniel Dumitrescu,et al.  Imatinib mesylate for the treatment of pulmonary arterial hypertension , 2012, Expert opinion on investigational drugs.

[18]  Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility Step 5 NOTE FOR GUIDANCE ON THE DETECTION OF TOXICITY TO REPRODUCTION FOR MEDICINAL PRODUCTS & TOXICITY TO MALE FERTILITY (CPMP/ICH/386/95) FINAL APPROVAL BY CPMP , 2006 .

[19]  Eva Frei,et al.  Native albumin for targeted drug delivery , 2010, Expert opinion on drug delivery.

[20]  A S Kesselheim,et al.  Permitting Product Liability Litigation for FDA‐Approved Drugs and Devices Promotes Patient Safety , 2010, Clinical pharmacology and therapeutics.

[21]  P. Toutain,et al.  Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. , 2004, Journal of veterinary pharmacology and therapeutics.

[22]  P B Watkins,et al.  Drug Safety Sciences and the Bottleneck in Drug Development , 2011, Clinical pharmacology and therapeutics.

[23]  Richard A. Harvey,et al.  Lippincott's Illustrated Reviews , 1987 .

[24]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[25]  Alain Schweitzer,et al.  Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and Development , 2010, The AAPS Journal.

[26]  Katarzyna R Przybylak,et al.  In silico models for drug-induced liver injury – current status , 2012, Expert opinion on drug metabolism & toxicology.

[27]  Gerhard Nahler,et al.  International Conference on Harmonisation (ICH) , 2009 .

[28]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[29]  Amrit Ray.  Beyond debacle and debate: developing solutions in drug safety , 2009, Nature Reviews Drug Discovery.

[30]  E. Mariman,et al.  Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[31]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[32]  K. Azzaoui,et al.  In vitro safety pharmacology profiling: what else beyond hERG? , 2009, Future medicinal chemistry.

[33]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[34]  Qing-Yu He,et al.  Genomic and proteomic approaches for predicting toxicity and adverse drug reactions , 2009 .

[35]  J. G. Slatter,et al.  Safety Testing of Drug Metabolites: Mist Guidance Impact on the Practice of Industrial Drug Metabolism , 2010 .

[36]  Richard S Paules,et al.  Use of transcriptomics in understanding mechanisms of drug-induced toxicity. , 2010, Pharmacogenomics.

[37]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[38]  E Z Dajani,et al.  Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[39]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[40]  Jaime Kulisevsky,et al.  Pergolide: Multiple-Dose Pharmacokinetics in Patients with Mild to Moderate Parkinson Disease , 2005, Clinical neuropharmacology.

[41]  M Clozel.  Endothelin receptor antagonist. , 2001, Heart failure reviews.

[42]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[43]  Chih-Hung Lee,et al.  α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain. , 2011, Biochemical pharmacology.

[44]  Saïk Urien,et al.  Concentration‐dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans , 2009 .

[45]  Michael Engwall,et al.  Translation between in vitro inhibition of the cardiac Nav1.5 channel and pre-clinical and clinical QRS widening , 2009 .

[46]  R. Finkel,et al.  Lippincott Illustrated Reviews: Pharmacology , 2014 .

[47]  P Y Muller,et al.  Safety Assessment and Dose Selection for First‐in‐Human Clinical Trials With Immunomodulatory Monoclonal Antibodies , 2009, Clinical pharmacology and therapeutics.

[48]  S. Härtter,et al.  A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. , 2006, Clinical therapeutics.

[49]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.